spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  aromatase inhibitor 

 HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2019
Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2017
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2017
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2016
IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Aug 2016
Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2015
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jul 2014
Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Sep 2011
FDA Approves New Indications for Prolia(R) (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2010
FDA Approves New Dosing for FASLODEX(R) (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2010
Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jul 2010
Clarient Announces Publication of Mammostrat(R) Breast Cancer Study in Breast Cancer Research
Diagnostics Oncology
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology
 HSMN NewsFeed - 7 May 2009
Ipsogen Launches a New Test to Guide Hormonotherapy Prescription in Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 11 Dec 2008
Femara(R) (letrozole) FIRST Aromatase Inhibitor to Indicate Overall Survival Benefit Versus tamoxifen When Taken for Five Years After Breast Cancer Surgery
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
Anastrozole Confirmed Superior in Breast Cancer Prevention
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jul 2007
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Meditrina Pharmaceuticals, Inc. Initiates Phase II Trial and Raises $4.4M in Initial Funding
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2006
Progress Reported Toward Development of a Breast Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 May 2006
NICE Initial Recommendation: One Step Closer to Backing Aromatase Inhibitor Treatment for Women With Early Breast Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 37 additional stories matching:
aromatase inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.